Suppliers / Zhejiang Ruibang Laboratories

Zhejiang Ruibang Laboratories

China Updated 9 July 2026

Zhejiang Ruibang Laboratories is a contract manufacturer based in China. It holds 3 active US drug master files and 2 valid CEPs across a filed portfolio of 4 molecules. Its most recent recorded inspection, by US FDA, closed on 21 July 2016 as VAI.

3
active US DMFs
2
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 July 2016 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Wenzhou, China Not on file
China, China 3001027745

What they file, and where

Molecule Regulators Docs
Calcium SFDA (Saudi Arabia), US FDA 2
Cyclosporine EDQM, US FDA 2
Calcium Gluconate EDQM 1
Thiostrepton US FDA 1

Also appears on these molecule pages

Calci contract manufacturing Ciclosporin contract manufacturing Cyclosporine contract manufacturing Lovastatin contract manufacturing Mupirocin contract manufacturing Orlistat contract manufacturing Simvastatin contract manufacturing

Questions about Zhejiang Ruibang Laboratories

Does Zhejiang Ruibang Laboratories hold a US DMF or a CEP?
Zhejiang Ruibang Laboratories holds 3 active US drug master files and 2 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Zhejiang Ruibang Laboratories FDA-registered?
One site operated by Zhejiang Ruibang Laboratories carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Zhejiang Ruibang Laboratories's last inspection go?
The most recent inspection on record closed on 21 July 2016 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 1 inspection is on file.
Where does Zhejiang Ruibang Laboratories manufacture?
2 registered sites are on record, in China (Wenzhou and China). Every site is listed on this page with the register it came from.
What does Zhejiang Ruibang Laboratories make?
4 molecules are on record against Zhejiang Ruibang Laboratories, including Calcium, Cyclosporine, Calcium Gluconate and Thiostrepton. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Ruibang Laboratories comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 21 July 2016.

Comparable suppliers

Apotex shares 2 molecules Concord Biotech shares 2 molecules CKD Bio shares 2 molecules TAPI Czech Industries s.r.o shares 2 molecules North China Pharmaceutical shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability